CONNECT WITH US
HealthTech

HealthTech

New pill combo approved for breast cancer that stops responding to hormone therapy

Medical Xpress logo

Published on

Add as a preferred source on Google
New pill combo approved for breast cancer that stops responding to hormone therapy

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

People with advanced breast cancer that has stopped responding to hormone therapy now have a new pill-based treatment option.

The U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly), a once-daily pill, on Monday. It's meant to be taken with the cancer drug everolimus.

The pairing is for adults with estrogen receptor (ER)-positive, HER2-negative breast cancer that has grown into nearby tissue or spread to other parts of the body.

ER-positive cancers feed on the hormone estrogen to grow. HER2-negative means the tumor doesn't make high levels of a growth protein called HER2.

Over time, though, many of these tumors develop a change in a gene called ESR1 that helps them slip past hormone drugs. Up to 40% of patients with this type of advanced breast cancer develop ESR1 mutations, Roche said in a news release.

The new approval covers only patients whose tumors carry that mutation and whose cancer came back or got worse despite earlier hormone therapy.

To find these patients, the FDA also authorized a blood test called FoundationOne Liquid CDx. It checks for bits of tumor DNA circulating in the bloodstream.

Giredestrant latches onto estrogen receptors on cancer cells, blocking estrogen and causing the receptors to break down. Everolimus shuts down a separate pathway that cancer cells use to grow.

The approval is based on a trial of 373 adults with ER+, HER2- breast cancer whose cancer had advanced after earlier treatment.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.